PMID- 34476643
OWN - NLM
STAT- MEDLINE
DCOM- 20220224
LR  - 20220224
IS  - 1436-3305 (Electronic)
IS  - 1436-3291 (Linking)
VI  - 25
IP  - 1
DP  - 2022 Jan
TI  - Radiological criteria for selecting candidates for neoadjuvant chemotherapy for 
      gastric cancer: an exploratory analysis from the PRODIGY study.
PG  - 170-179
LID - 10.1007/s10120-021-01243-z [doi]
AB  - BACKGROUND: In this exploratory analysis from the PRODIGY study, we aimed to 
      define the radiological criteria to identify patients with gastric cancer who may 
      derive maximal clinical benefit from neoadjuvant chemotherapy. PATIENTS AND 
      METHODS: There were 246 patients allocated to receive surgery followed by 
      adjuvant S-1 (SC group) and 238 allocated to receive neoadjuvant chemotherapy 
      (CSC group). As the PRODIGY's radiological method of lymph node (LN) evaluation 
      considers short diameter and morphology (the size and morphology method), a 
      method considering only short diameter was also employed. In the SC group, the 
      correlation between radiologic and pathologic findings was analyzed. The hazard 
      ratio (HR) for the progression-free survival (PFS) of the CSC group was analyzed 
      in subgroups with different cT/N stages. RESULTS: cT4 disease showed a 
      sensitivity of 85.6% for detecting pT4 and had a low proportion of pathologic 
      stage (pStage) I disease (4.5%). Among the criteria determined by different cT/N 
      stages by each method of LN positivity, those involving cT4Nany or cT4N + by both 
      methods had a minimal proportion of pStage I disease (</= 5%), while cT4Nany by 
      both methods and cT4N + by the size and morphology method exhibited >/= 75.9% 
      sensitivity for detecting pStage III disease. The relative risk reduction in PFS 
      of the CSC group was greatest in patients meeting the cT4Nany criterion defined 
      by both methods (HR 0.67, 95% confidence interval 0.48-0.93). CONCLUSIONS: The 
      cT4Nany criterion, regardless of the radiological method used for LN evaluation, 
      may help select patients with resectable gastric cancer for neoadjuvant 
      chemotherapy.
CI  - (c) 2021. The International Gastric Cancer Association and The Japanese Gastric 
      Cancer Association.
FAU - Kim, Hyung-Don
AU  - Kim HD
AD  - Department of Oncology, Asan Medical Center, University of Ulsan College of 
      Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
FAU - Lee, Jong Seok
AU  - Lee JS
AD  - Department of Radiology, Asan Medical Center, University of Ulsan College of 
      Medicine, Seoul, Republic of Korea.
FAU - Yook, Jeong Hwan
AU  - Yook JH
AD  - Department of Surgery, Asan Medical Center, University of Ulsan College of 
      Medicine, Seoul, Republic of Korea.
FAU - Ryu, Min-Hee
AU  - Ryu MH
AD  - Department of Oncology, Asan Medical Center, University of Ulsan College of 
      Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
FAU - Park, Young-Kyu
AU  - Park YK
AD  - Department of Surgery, Chonnam National University Medical School, Hwasun, 
      Republic of Korea.
FAU - Kim, Jin Young
AU  - Kim JY
AD  - Division of Hemato-Oncology, Department of Internal Medicine, Dongsan Medical 
      Center, Keimyung University School of Medicine, Daegu, Republic of Korea.
FAU - Kim, Young-Woo
AU  - Kim YW
AD  - Center for Gastric Cancer, Graduate School of Cancer Science and Policy, Research 
      Institute and Hospital, National Cancer Center, Goyang, Republic of Korea.
FAU - Oh, Sang Cheul
AU  - Oh SC
AD  - Department of Internal Medicine, Korea University Guro Hospital, Seoul, Republic 
      of Korea.
FAU - Kim, Jong Gwang
AU  - Kim JG
AD  - Department of Internal Medicine, Kyungpook National University, Daegu, Republic 
      of Korea.
FAU - Cheong, Jae-Ho
AU  - Cheong JH
AD  - Department of Surgery, Yonsei University College of Medicine, Seoul, 03722, 
      Republic of Korea.
FAU - Jeong, Oh
AU  - Jeong O
AD  - Department of Surgery, Chonnam National University Medical School, Hwasun, 
      Republic of Korea.
FAU - Noh, Sung Hoon
AU  - Noh SH
AD  - Department of Surgery, Yonsei University College of Medicine, Seoul, 03722, 
      Republic of Korea.
FAU - Kang, Yoon-Koo
AU  - Kang YK
AUID- ORCID: 0000-0003-0783-6583
AD  - Department of Oncology, Asan Medical Center, University of Ulsan College of 
      Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. 
      ykkang@amc.seoul.kr.
LA  - eng
PT  - Journal Article
DEP - 20210902
PL  - Japan
TA  - Gastric Cancer
JT  - Gastric cancer : official journal of the International Gastric Cancer Association 
      and the Japanese Gastric Cancer Association
JID - 100886238
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Chemotherapy, Adjuvant
MH  - Humans
MH  - Lymph Nodes/pathology
MH  - *Neoadjuvant Therapy/adverse effects
MH  - Neoplasm Staging
MH  - *Stomach Neoplasms/diagnostic imaging/drug therapy/pathology
OTO - NOTNLM
OT  - Gastric cancer
OT  - Lymph node staging
OT  - Neoadjuvant chemotherapy
OT  - Radiological criteria
EDAT- 2021/09/04 06:00
MHDA- 2022/02/25 06:00
CRDT- 2021/09/03 07:03
PHST- 2021/06/23 00:00 [received]
PHST- 2021/08/24 00:00 [accepted]
PHST- 2021/09/04 06:00 [pubmed]
PHST- 2022/02/25 06:00 [medline]
PHST- 2021/09/03 07:03 [entrez]
AID - 10.1007/s10120-021-01243-z [pii]
AID - 10.1007/s10120-021-01243-z [doi]
PST - ppublish
SO  - Gastric Cancer. 2022 Jan;25(1):170-179. doi: 10.1007/s10120-021-01243-z. Epub 
      2021 Sep 2.